Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Janus Henderson Group PLC

Janus Henderson Group PLC cut its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 94.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,402 shares of the company’s stock after selling 305,893 shares during the quarter. Janus Henderson Group PLC’s holdings in Harmony Biosciences were worth $459,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in HRMY. Dimensional Fund Advisors LP raised its holdings in shares of Harmony Biosciences by 13.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,076,510 shares of the company’s stock worth $58,157,000 after purchasing an additional 245,784 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Harmony Biosciences by 109.9% in the 1st quarter. SG Americas Securities LLC now owns 2,018,174 shares of the company’s stock valued at $56,529,000 after buying an additional 1,056,507 shares during the period. State Street Corp grew its position in shares of Harmony Biosciences by 0.5% during the 4th quarter. State Street Corp now owns 1,661,850 shares of the company’s stock valued at $62,186,000 after buying an additional 8,246 shares during the last quarter. LSV Asset Management grew its position in shares of Harmony Biosciences by 3.9% during the 4th quarter. LSV Asset Management now owns 1,657,093 shares of the company’s stock valued at $62,008,000 after buying an additional 62,200 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Harmony Biosciences by 15.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,491,605 shares of the company’s stock worth $55,816,000 after acquiring an additional 196,224 shares during the period. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Price Performance

Shares of HRMY opened at $39.00 on Tuesday. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of 12.66, a price-to-earnings-growth ratio of 0.37 and a beta of 0.96. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.45 and a current ratio of 3.48. Harmony Biosciences Holdings, Inc. has a one year low of $25.52 and a one year high of $40.87. The stock’s fifty day moving average is $35.34 and its 200-day moving average is $32.61.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $1.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.96 by $0.32. The business had revenue of $261.28 million for the quarter, compared to analysts’ expectations of $250.77 million. Harmony Biosciences had a net margin of 18.88% and a return on equity of 20.06%. The company’s revenue was up 30.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.92 earnings per share. Equities analysts anticipate that Harmony Biosciences Holdings, Inc. will post 3.62 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on HRMY shares. UBS Group restated a “neutral” rating and issued a $37.00 target price on shares of Harmony Biosciences in a research note on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating and set a $55.00 price target on shares of Harmony Biosciences in a research report on Thursday, July 16th. Zacks Research raised Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. Wall Street Zen upgraded Harmony Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Weiss Ratings upgraded Harmony Biosciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.50.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.